At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GNLX Genelux Corporation
Trading 10-22 11:22:09 EDT
2.11
+0.04
+1.93%
High2.17Low1.97Vol305.66K
Open2.16D1 Closing2.07Amplitude9.66%
Mkt Cap95.46MTradable Cap77.85MTotal Shares45.25M
T/O617.30KT/O Rate0.83%Tradable Shares36.90M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Genelux assumed with a Buy at Lucid Capital
TIPRANKS  ·  09-17
Genelux assumed with a Buy at Lucid Capital
Genelux publishes case report from dose escalation portion of OLVI-VEC-202-SCLC
TIPRANKS  ·  09-10
Genelux publishes case report from dose escalation portion of OLVI-VEC-202-SCLC
Genelux Reports 16.7-Month PFS in Phase 1b/2 Olvi-Vec Trial Case Study for Platinum-Relapsed SCLC
Reuters  ·  09-10
Genelux Reports 16.7-Month PFS in Phase 1b/2 Olvi-Vec Trial Case Study for Platinum-Relapsed SCLC
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
GlobeNewswire  ·  09-10
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
Genelux Publishes Corporate Presentation Highlighting Olvi-Vec Late-Stage Ovarian Cancer Program Focused on Platinum Sensitization
Reuters  ·  08-14
Genelux Publishes Corporate Presentation Highlighting Olvi-Vec Late-Stage Ovarian Cancer Program Focused on Platinum Sensitization
Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate
Benzinga Earnings  ·  08-14
Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate
Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses
Reuters  ·  08-14
Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses
Press Release: Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
Dow Jones  ·  08-14
Press Release: Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
Genelux Q2 FY26 Net Loss Widens to $9.47 Million; Revenue Flat at no Revenue
Reuters  ·  08-14
Genelux Q2 FY26 Net Loss Widens to $9.47 Million; Revenue Flat at no Revenue
Genelux Corp Expected to Post a Loss of 20 Cents a Share - Earnings Preview
Reuters  ·  08-01
Genelux Corp Expected to Post a Loss of 20 Cents a Share - Earnings Preview
Attovia Therapeutics Appoints John W. Smither to Board of Directors
THOMSON REUTERS  ·  07-15
Attovia Therapeutics Appoints John W. Smither to Board of Directors
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-30
Wall Street Analysts Are Bullish on Top Healthcare Picks
Genelux Reports Viro-15 Translational Analysis Supports Olvi-vec Immune Activation, Platinum Resensitization in Ovarian Cancer
Reuters  ·  06-30
Genelux Reports Viro-15 Translational Analysis Supports Olvi-vec Immune Activation, Platinum Resensitization in Ovarian Cancer
Genelux shareholders elect John Smither to board at annual meeting
Reuters  ·  06-23
Genelux shareholders elect John Smither to board at annual meeting
Genelux director Thomas John disposes of 10,000 common shares worth $29,801
Reuters  ·  06-03
Genelux director Thomas John disposes of 10,000 common shares worth $29,801
Genelux Corp reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-08
Genelux Corp reports results for the quarter ended March 31 - Earnings Summary
Genelux Q1 net loss widens, misses analyst expectations
Reuters  ·  05-08
Genelux Q1 net loss widens, misses analyst expectations
Genelux Q1 EPS $(0.20), Inline
Benzinga Earnings  ·  05-08
Genelux Q1 EPS $(0.20), Inline
Genelux Q1 2026 net loss widens to $8.9 million; no revenue
Reuters  ·  05-08
Genelux Q1 2026 net loss widens to $8.9 million; no revenue
Press Release: Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
Dow Jones  ·  05-08
Press Release: Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Introduction

Company Name.
Genelux Corporation
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Issue price:
--